Special Issue "Guidelines, New Data and Real-World Evidence with Oral Anticoagulants"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 December 2021).

Special Issue Editor

Dr. Giuseppe Andò
E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy
Interests: oral anticoagulants (OAC); atrial fibrillation; acute coronary syndrome; percutaneous coronary intervention (PCI); guidelines
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There has been considerable progress in the pharmacology of oral anticoagulants (OAC) over the last twenty years, and non-vitamin K antagonists OAC (NOAC) have dramatically changed clinical practice. NOAC have demonstrated a favorable risk–benefit profile in patients with atrial fibrillation and with venous thromboembolism in phase III trials, although real-world evidence highlights that several issues in the implementation of NOAC in clinical practice still remain unresolved in specific subsets. On the other hand, re-emerging concepts on the pathophysiology of atherothrombosis have paved the way for a new therapeutic option consisting in the association of antiplatelet and low-dose NOAC, known as dual pathway inhibition. While guidelines issued by scientific societies summarize and evaluate available evidence to facilitate clinicians in their decision making for daily practice, continuously evolving research introduces new diagnostic algorithms and challenges therapeutic concepts. The present Special Issue has been thought to provide an overview of the latest evidence in the field of OAC focusing on both diagnostic and therapeutic advances and highlighting their implications for patients’ prognosis. Therefore, we welcome the submission of review articles as well as original research papers dealing with the topics of guidelines, new data, and real-world evidence about OAC in atrial fibrillation, atherothrombosis, and venous thromboembolism.

Dr. Giuseppe Andò
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • oral anticoagulants (OAC)
  • atrial fibrillation
  • stroke
  • venous thromboembolism (VTE)
  • dual pathway inhibition (DPI)
  • coronary artery disease (CAD)
  • peripheral artery disease (PAD)
  • real-world evidence (RWE)

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease
Medicina 2021, 57(5), 422; https://doi.org/10.3390/medicina57050422 - 27 Apr 2021
Viewed by 792
Over the past few decades, a series of innovative medicines have been developed in order to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor [...] Read more.
Over the past few decades, a series of innovative medicines have been developed in order to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and factor Xa have been successfully licensed providing a more predictable effect and better safety profile compared to conventional anticoagulants (heparins and vitamin K antagonists (VKAs)). However, comparative efficacy and safety data is limited in patients with advanced chronic kidney disease (i.e., CKD stage 4/5 and end stage renal disease) because patients with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 were actively excluded from landmark trials, thus representing a major clinical limitation for the currently available agents. However, the renal function of AF patients can be altered over time. On the other hand, patients with CKD have an increased risk of developing AF. This review article will provide an overview of current concepts and recent evidence guiding the clinical use of NOACs in patients with CKD requiring chronic anticoagulation, and the associated risks and benefits of treatment in this specific patient population. Full article
(This article belongs to the Special Issue Guidelines, New Data and Real-World Evidence with Oral Anticoagulants)
Show Figures

Figure 1

Back to TopTop